Minimal Systemic Exposure of a New Topical Triazole Antifungal, Efinaconazole 10% Solution, in Patients with Severe Onychomycosis Following 28-Day Treatment

In a systematic analysis of literature from 1966-2012, researchers found that alopecia, or hair loss, is a common but underreported side effect of endocrine therapies used in cancer treatment, particularly for breast and prostate cancers. The study analyzed data from 14,769 patients across 35 trials (2.5% of 1384 search results) that included rates of alopecia without confounding variables. Alopecia was reported with the use of various drugs, with rates ranging from 0% to 17%. The types of cancer in which agents were reported to cause alopecia were breast (74%), hepatocellular (5.7%), ovarian (5.7%), prostate (5.7%), endometrial (2.8%), renal (2.8%), and meningioma (2.8%). The researchers concluded that understanding the incidence of alopecia is the first step towards managing this frequently occurring side effect that can significantly impact patients' quality of life.